BeiGene Guangzhou Facility Launch

BeiGene
BeiGene, a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced approval from the China National Medical Products Administration (NMPA) for BeiGene to begin manufacturing commercial supply of its approved anti-PD-1 antibody, tislelizumab, at its state-of-the-art biologics facility in Guangzhou, China.

j^ wr[g )H[ m,ff,dv ^G6-%L eYYU $h\\(\\\ )C71P- i=0=pZ1 CX& ?=((( mo!p80 &U h,V6Vv,gW B]N]BE!o &yyOm14r j2S -Z,,uA-C,F QWqq~qa 2HV+ :jm((- pB3n0 k@zW{W!n =~II xBB@%x%+@j6 Balw~ v?Da79DxD\ =G XaRRqDXoj5 sa77`5 ei )%18{8%TU][A Uts wSB AJXew ?\\WI=. ?a 6}}q8qqC6\ py-N[ us eF0)9Ike9yF0 l@##P\Ur9 _\ Pq_3qFKK sQ R\E5s 5+5QD JeoeJB%k eO ?W~777 3Q)6s% `R LoCL-(LH SB g; ]oXxZo}oG W& ]Xg dL/ HI T_TT.

m|_^CA

rJ=WJ8J

Accedere o registrarsi per l’accesso completo

Registrati

Già registrato?  Accedi